within Pharmacolibrary.Drugs.ATC.A;

model A10BB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Glibornuride is an oral sulfonylurea antidiabetic agent used for the treatment of type 2 diabetes mellitus by stimulating insulin secretion from pancreatic beta cells. It has been withdrawn or is rarely used today due to the availability of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult population due to absence of specific published human PK models. Parameters are estimated from available product characteristics and reference-class data.</p><h4>References</h4><ol><li>G Rentsch, H A Schmidt, J Rieder,[Pharmacokinetics of glibornuride].,Arzneimittel-Forschung,1972<a href='https://pubmed.ncbi.nlm.nih.gov/4679250/'>https://pubmed.ncbi.nlm.nih.gov/4679250/</a></li><li>K Stoeckel, V Trueb, U C Dubach, R C Heintz, V Ascalone, I Forgo, U Hennes,Lack of effect of tenoxicam on glibornuride kinetics and response.,British journal of clinical pharmacology,1985<a href='https://pubmed.ncbi.nlm.nih.gov/3157397/'>https://pubmed.ncbi.nlm.nih.gov/3157397/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BB04;
